| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Shin-ichi Uchida, Kazuhiro Soshiroda, Eri Okita, Mika Kawai-Uchida, Akihisa Mori, Peter Jenner, Tomoyuki Kand. The adenosine A2A receptor antagonist, istradefylline enhances anti-parkinsonian activity induced by combined treatment with low doses of L-DOPA and dopamine agonists in MPTP-treated common marmosets. European journal of pharmacology. vol 766. 2016-08-18. PMID:26415982. |
the adenosine a2a receptor antagonist, istradefylline improves motor function in patients with advanced parkinson's disease (pd) optimally treated with a combination of l-dopa and a dopamine agonist without increasing the risk of troublesome dyskinesia. |
2016-08-18 |
2023-08-13 |
marmoset |
| Shin-ichi Uchida, Kazuhiro Soshiroda, Eri Okita, Mika Kawai-Uchida, Akihisa Mori, Peter Jenner, Tomoyuki Kand. The adenosine A2A receptor antagonist, istradefylline enhances anti-parkinsonian activity induced by combined treatment with low doses of L-DOPA and dopamine agonists in MPTP-treated common marmosets. European journal of pharmacology. vol 766. 2016-08-18. PMID:26415982. |
with threshold doses of the dopamine agonists enhanced their anti-parkinsonian effect that led to increased 'on' time without dyskinesia appearing. |
2016-08-18 |
2023-08-13 |
marmoset |
| Shin-ichi Uchida, Kazuhiro Soshiroda, Eri Okita, Mika Kawai-Uchida, Akihisa Mori, Peter Jenner, Tomoyuki Kand. The adenosine A2A receptor antagonist, istradefylline enhances anti-parkinsonian activity induced by combined treatment with low doses of L-DOPA and dopamine agonists in MPTP-treated common marmosets. European journal of pharmacology. vol 766. 2016-08-18. PMID:26415982. |
with the threshold doses of dopamine agonists and the suboptimal dose of l-dopa in a triple combination caused a further enhancement of the anti-parkinsonian response but dyskinesia was still absent. |
2016-08-18 |
2023-08-13 |
marmoset |
| Shin-ichi Uchida, Kazuhiro Soshiroda, Eri Okita, Mika Kawai-Uchida, Akihisa Mori, Peter Jenner, Tomoyuki Kand. The adenosine A2A receptor antagonist, istradefylline enhances anti-parkinsonian activity induced by combined treatment with low doses of L-DOPA and dopamine agonists in MPTP-treated common marmosets. European journal of pharmacology. vol 766. 2016-08-18. PMID:26415982. |
in early pd, dopamine agonists are often used as first-line monotherapy, but efficacy is usually lost within a few years, at which time l-dopa is added but with the risk of dyskinesia appearance. |
2016-08-18 |
2023-08-13 |
marmoset |
| Daniel Farré, Ana Muñoz, Estefanía Moreno, Irene Reyes-Resina, Júlia Canet-Pons, Iria G Dopeso-Reyes, Alberto J Rico, Carme Lluís, Josefa Mallol, Gemma Navarro, Enric I Canela, Antonio Cortés, José L Labandeira-García, Vicent Casadó, José L Lanciego, Rafael Franc. Stronger Dopamine D1 Receptor-Mediated Neurotransmission in Dyskinesia. Molecular neurobiology. vol 52. issue 3. 2016-08-10. PMID:25344317. |
stronger dopamine d1 receptor-mediated neurotransmission in dyskinesia. |
2016-08-10 |
2023-08-13 |
rat |
| Daniel Farré, Ana Muñoz, Estefanía Moreno, Irene Reyes-Resina, Júlia Canet-Pons, Iria G Dopeso-Reyes, Alberto J Rico, Carme Lluís, Josefa Mallol, Gemma Navarro, Enric I Canela, Antonio Cortés, José L Labandeira-García, Vicent Casadó, José L Lanciego, Rafael Franc. Stronger Dopamine D1 Receptor-Mediated Neurotransmission in Dyskinesia. Molecular neurobiology. vol 52. issue 3. 2016-08-10. PMID:25344317. |
d1 receptors heteromerize with dopamine d3 receptors, which are considered therapeutic targets for dyskinesia in parkinsonian patients. |
2016-08-10 |
2023-08-13 |
rat |
| N Brehm, F Bez, T Carlsson, B Kern, S Gispert, G Auburger, M A Cenc. A Genetic Mouse Model of Parkinson's Disease Shows Involuntary Movements and Increased Postsynaptic Sensitivity to Apomorphine. Molecular neurobiology. vol 52. issue 3. 2016-08-08. PMID:25307288. |
the striatal presynaptic dopamine deficit is alleviated by treatment with levodopa (l-dopa), but postsynaptic plastic changes induced by this treatment lead to a development of involuntary movements (dyskinesia). |
2016-08-08 |
2023-08-13 |
mouse |
| Nicoletta Schintu, Xiaoqun Zhang, Alexandra Alvarsson, Roberta Marongiu, Michael G Kaplitt, Paul Greengard, Per Svenningsso. p11 modulates L-DOPA therapeutic effects and dyskinesia via distinct cell types in experimental Parkinsonism. Proceedings of the National Academy of Sciences of the United States of America. vol 113. issue 5. 2016-08-08. PMID:26787846. |
restoration of dopamine transmission by levodopa (l-dopa) relieves motor symptoms of pd but often causes disabling dyskinesias. |
2016-08-08 |
2023-08-13 |
mouse |
| Nicoletta Schintu, Xiaoqun Zhang, Alexandra Alvarsson, Roberta Marongiu, Michael G Kaplitt, Paul Greengard, Per Svenningsso. p11 modulates L-DOPA therapeutic effects and dyskinesia via distinct cell types in experimental Parkinsonism. Proceedings of the National Academy of Sciences of the United States of America. vol 113. issue 5. 2016-08-08. PMID:26787846. |
in contrast, mice lacking p11 in dopamine d1r-containing neurons exhibit tremor and rotational responses toward l-dopa, but develop less dyskinesia. |
2016-08-08 |
2023-08-13 |
mouse |
| Doris E Payer, Mark Guttman, Stephen J Kish, Junchao Tong, John R Adams, Pablo Rusjan, Sylvain Houle, Yoshiaki Furukawa, Alan A Wilson, Isabelle Boilea. D3 dopamine receptor-preferring [11C]PHNO PET imaging in Parkinson patients with dyskinesia. Neurology. vol 86. issue 3. 2016-05-26. PMID:26718579. |
d3 dopamine receptor-preferring [11c]phno pet imaging in parkinson patients with dyskinesia. |
2016-05-26 |
2023-08-13 |
Not clear |
| Svetlana A Ivanova, Anton J M Loone. Levodopa-Induced Dyskinesia Is Related to Indirect Pathway Medium Spiny Neuron Excitotoxicity: A Hypothesis Based on an Unexpected Finding. Parkinson's disease. vol 2016. 2016-05-04. PMID:27144051. |
particularly the combination of increased oxidative stress due to aberrant dopamine metabolism, increased vulnerability to nmda induced excitotoxicity, and the particular sensitivity of indirect pathway medium spiny neurons for this excitotoxicity may explain the observed increased prevalence of levodopa-induced dyskinesia. |
2016-05-04 |
2023-08-13 |
Not clear |
| Lufei Shan, Oscar Diaz, Yajun Zhang, Bruce Ladenheim, Jean-Lud Cadet, Yung-Hsiao Chiang, Lars Olson, Barry J Hoffer, Cristina M Bäckma. L-Dopa induced dyskinesias in Parkinsonian mice: Disease severity or L-Dopa history. Brain research. vol 1618. 2016-04-25. PMID:26086365. |
using mitopark mice, that models mitochondrial failure in dopamine (da) neurons and mimics the progressive loss of dopamine observed in parkinson's disease, we found that the severity of da denervation and associated adaptations in striatal neurotransmission at the time of initiation of l-dopa treatment determines development of l-dopa induced dyskinesias. |
2016-04-25 |
2023-08-13 |
mouse |
| Gurdal Sahin, Lachlan H Thompson, Sonia Lavisse, Merve Ozgur, Latifa Rbah-Vidal, Frédéric Dollé, Philippe Hantraye, Deniz Kiri. Differential dopamine receptor occupancy underlies L-DOPA-induced dyskinesia in a rat model of Parkinson's disease. PloS one. vol 9. issue 3. 2016-03-31. PMID:24614598. |
the prevailing view for the underlying presynaptic mechanism of l-dopa-induced dyskinesia (lid) suggests that surges in dopamine (da) via uncontrolled release from serotonergic terminals results in abnormally high level of extracellular striatal dopamine. |
2016-03-31 |
2023-08-12 |
rat |
| Pedro Barroso-Chinea, Marie-Laure Thiolat, Simone Bido, Audrey Martinez, Evelyne Doudnikoff, Jérôme Baufreton, Mathieu Bourdenx, Bertrand Bloch, Erwan Bezard, Marie-Laure Martin-Negrie. D1 dopamine receptor stimulation impairs striatal proteasome activity in Parkinsonism through 26S proteasome disassembly. Neurobiology of disease. vol 78. 2016-03-28. PMID:25766677. |
among the mechanisms underlying the development of l-dopa-induced dyskinesia (lid) in parkinson's disease, complex alterations in dopamine signaling in d1 receptor (d1r)-expressing medium spiny striatal neurons have been unraveled such as, but not limited to, dysregulation of d1r expression, lateral diffusion, intraneuronal trafficking, subcellular localization and desensitization, leading to a pathological anchorage of d1r at the plasma membrane. |
2016-03-28 |
2023-08-13 |
Not clear |
| Alexandra Alvarsson, Xiaoqun Zhang, Tiberiu L Stan, Nicoletta Schintu, Banafsheh Kadkhodaei, Mark J Millan, Thomas Perlmann, Per Svenningsso. Modulation by Trace Amine-Associated Receptor 1 of Experimental Parkinsonism, L-DOPA Responsivity, and Glutamatergic Neurotransmission. The Journal of neuroscience : the official journal of the Society for Neuroscience. vol 35. issue 41. 2016-01-19. PMID:26468205. |
restoration of dopamine transmission by l-dopa relieves symptoms of pd but causes dyskinesia. |
2016-01-19 |
2023-08-13 |
mouse |
| T Bordia, M McGregor, J M McIntosh, R M Drenan, M Qui. Evidence for a role for α6(∗) nAChRs in l-dopa-induced dyskinesias using Parkinsonian α6(∗) nAChR gain-of-function mice. Neuroscience. vol 295. 2016-01-13. PMID:25813704. |
l-dopa-induced dyskinesias (lids) are a serious side effect of dopamine replacement therapy for parkinson's disease. |
2016-01-13 |
2023-08-13 |
mouse |
| Philippe Huo. L-DOPA-induced dyskinesia, is striatal dopamine depletion a requisite? Journal of the neurological sciences. vol 351. issue 1-2. 2016-01-11. PMID:25758471. |
research suggests that striatal dopamine depletion is an important aetiological factor leading to dyskinesia development. |
2016-01-11 |
2023-08-13 |
human |
| M Y Wong, A Borgkvist, S J Choi, E V Mosharov, N S Bamford, D Sulze. Dopamine-dependent corticostriatal synaptic filtering regulates sensorimotor behavior. Neuroscience. vol 290. 2015-12-15. PMID:25637802. |
after loss of nigrostriatal dopamine axons in parkinson's disease, l-3,4-dihydroxyphenlalanine (l-dopa) and dopamine d2-like receptor agonists are used as replacement therapy, although these drugs also trigger sensitized sensorimotor responses including dyskinesias and impulse control disorders. |
2015-12-15 |
2023-08-13 |
mouse |
| Nikhil M Urs, Simone Bido, Sean M Peterson, Tanya L Daigle, Caroline E Bass, Raul R Gainetdinov, Erwan Bezard, Marc G Caro. Targeting β-arrestin2 in the treatment of L-DOPA-induced dyskinesia in Parkinson's disease. Proceedings of the National Academy of Sciences of the United States of America. vol 112. issue 19. 2015-12-14. PMID:25918399. |
parkinson's disease (pd) is characterized by severe locomotor deficits and is commonly treated with the dopamine (da) precursor l-3,4-dihydroxyphenylalanine (l-dopa), but its prolonged use causes dyskinesias referred to as l-dopa-induced dyskinesias (lids). |
2015-12-14 |
2023-08-13 |
mouse |
| Arun Singh, Li Liang, Yoshiki Kaneoke, Xuebing Cao, Stella M Pap. Dopamine regulates distinctively the activity patterns of striatal output neurons in advanced parkinsonian primates. Journal of neurophysiology. vol 113. issue 5. 2015-12-01. PMID:25505120. |
nonbursty msns fired irregularly with marked pausing that increased in the on state in the msn subset with a levodopa response compatible with dopamine d2 receptor activation (indirect pathway msns), although the pause increase was not sustained in some units during the appearance of dyskinesias. |
2015-12-01 |
2023-08-13 |
monkey |